BEIJING -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that Adcendo ApS (“Adcendo”), a biotech company focused on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, has exercised its option under a research, option and license agreement to utilize Biocytogen’s fully human antibodies to further expand its ADC pipeline.

“We are excited to deploy Biocytogen’s cutting-edge platforms for antibody discovery to support Adcendo’s innovative ADC drug development initiatives,” said Yuelei Shen, Ph.D., president and CEO of Biocytogen. “Our unique RenMice® platform enables the discovery of fully human antibodies with high affinity, low immunogenicity, and favorable developability. With Adcendo’s extensive expertise in ADCs, we are confident that this collaboration will drive the rapid advancement of novel therapies to benefit patients worldwide.”

Michael Pehl, Chief Executive Officer of Adcendo, stated, “Our collaboration with Biocytogen marks a key advancement in developing first-in-class ADCs for cancers with significant unmet medical need. By combining Biocytogen’s advanced antibody platforms with Adcendo’s ADC expertise, we can accelerate the development of novel ADC therapies. This collaboration strengthens our capabilities and brings us closer to delivering transformative treatments for patients in need.”